Genocea Biosciences Inc. Stock
Your prediction
Genocea Biosciences Inc. Stock
Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Pros and Cons of Genocea Biosciences Inc. in the next few years
Pros
Cons
Performance of Genocea Biosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -2.990% | 3.235% | 54.512% | -50.424% | -5.476% | -47.871% | -92.305% |
| Evolus Inc | -1.160% | 15.568% | 50.757% | -48.757% | -3.156% | -30.553% | -28.190% |
| Sangamo Therapeutics Inc. | 50.930% | 35.092% | -41.262% | -71.434% | -56.089% | -87.325% | -98.221% |
Comments
